Singapore: The GBI Research has revealed that the non-small cell lung cancer (NSCLC) therapeutics market value in the As...
The fifth edition of the annual BioSpectrum Asia Pacific clinical research organization (CRO) Survey, which is conduct...
Singapore: Brisbane-based pharma firm Alchemia has appointed Mr Charles (Charlie) Walker as its chief executive officer....
Singapore: Patrys, an Australian clinical stage biopharmaceutical company, has completed the initial treatment of the fi...
Singapore: Associate Professor Tiziano Barberi and Dr Isabella Mengarelli from the Australian Regenerative Medicine Inst...
Singapore: US-based Echo Therapeutics, a company developing its needle-free Symphony tCGM System as a non-invasive, wire...
Singapore: Australian biotechnology company Minomic is all set to launch two overseas trials of its MiStat prostate canc...
Singapore: According to a survey by Accenture, majority of Australian doctors (77 percent) have highlighted that sharing...
‎Singapore: ReSearch Pharmaceutical Services, a clinical research firm, has appointed Mr Marc Wolff as its chief f...
Singapore: Phylogica, a public Australian peptide drug discovery company, has achieved a research milestone under its co...
Singapore: Australian drug discovery and development company Alchemia has appointed Dr Susan Kelley and Mr Nathan Drona ...
Singapore: Patrys, a clinical stage biotechnology company, has received approval to progress its Phase I/IIa PAT-SM6 mul...
Australia-based Hatchtech, which was started in October 2001, is developing a new generation of low-toxicity ovacides fo...
Q: How do you look at the nano-biotech achievements in India so far? Have the applications been enough?Dr Pachauri: I th...
Singapore: Researchers from St Vincent's Institute of Medical Research in Melbourne, Australia, in collaboration with re...
Singapore: Universal Biosensors reported its unaudited financial result for FY 2012 including a doubling of total revenu...
Singapore: Pfizer has revealed that its phase III study of INLYTA (axitinib) did not meet the primary endpoint of demons...
Driving in the niche industry of sleep disorders, ResMed was aggressive in strengthening its portfolio through acquisiti...
